2019 American Society of Clinical Oncology Annual Meeting*

Download All
May 31 - June 4, 2019; Chicago, Illinois
Review slidesets and analyses of key data from the 2019 Oncology meeting.

Genitourinary Cancers

Capsule Summary Slidesets

Darolutamide improves outcomes while maintaining quality of life in nonmetastatic CRPC.

Released: June 2, 2019

Apalutamide plus ADT significantly improved OS and rPFS vs placebo plus ADT in patients with metastatic castration-sensitive prostate cancer.

Released: June 7, 2019

Enzalutamide plus ADT significantly improved OS compared with standard nonsteroidal antiandrogen plus ADT in patients with mHSPC.

Released: June 6, 2019

EV-201 data showed a response rate of 44% with enfortumab vedotin in patients with advanced urothelial cancer who progressed after platinum chemotherapy and checkpoint inhibitors.

Released: June 7, 2019
Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Astellas and Seattle Genetics, Inc.
Bayer HealthCare Pharmaceuticals Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.